Sandra J. Horning
#145,908
Most Influential Person Now
Sandra J. Horning's AcademicInfluence.com Rankings
Sandra J. Horningphilosophy Degrees
Philosophy
#7852
World Rank
#11120
Historical Rank
Logic
#4886
World Rank
#6220
Historical Rank
Download Badge
Philosophy
Why Is Sandra J. Horning Influential?
(Suggest an Edit or Addition)Sandra J. Horning's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A predictive model for aggressive non-Hodgkin's lymphoma. (1993) (4400)
- Revised response criteria for malignant lymphoma. (2007) (4137)
- Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. (1999) (3170)
- Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. (2006) (1256)
- The natural history of initially untreated low-grade non-Hodgkin's lymphomas. (1984) (906)
- Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. (1997) (822)
- Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. (1990) (449)
- Natural history of and therapy for the indolent non-Hodgkin's lymphomas. (1993) (405)
- Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. (1982) (378)
- ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. (2012) (362)
- Female Reproductive Potential after Treatment for Hodgkin's Disease (1981) (354)
- Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. (2004) (325)
- High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. (1997) (320)
- Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. (2005) (319)
- Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. (2002) (317)
- Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. (2009) (277)
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. (2006) (266)
- Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. (2005) (264)
- Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. (2006) (254)
- Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). (2013) (246)
- Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. (2007) (240)
- Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. (2004) (228)
- Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. (2013) (228)
- Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. (1997) (222)
- Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. (2004) (203)
- Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. (1986) (195)
- Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. (2011) (194)
- Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. (2003) (193)
- Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. (1995) (191)
- Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. (2012) (189)
- Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) (2008) (179)
- Long-term survival after histologic transformation of low-grade follicular lymphoma. (1995) (171)
- Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. (2013) (159)
- Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. (2005) (156)
- High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. (2001) (156)
- Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. (2014) (154)
- Histiocytic malignancies: Morphologic, immunologic, and enzymatic heterogeneity (1984) (147)
- Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. (1988) (123)
- Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. (1998) (122)
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. (2010) (122)
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. (2013) (119)
- The immunologic and clinicopathologic heterogeneity of cutaneous lymphomas other than mycosis fungoides. (1983) (117)
- CYCLICAL COMBINATION CHEMOTHERAPY AND GONADAL FUNCTION (1979) (116)
- Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma (2007) (116)
- Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant (2013) (115)
- Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. (2005) (109)
- Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. (1984) (106)
- Treatment approaches to the low-grade lymphomas. (1994) (105)
- Utility of influenza vaccination for oncology patients. (2010) (104)
- The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 (2013) (103)
- Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis (2006) (103)
- Non‐Hodgkin lymphoma of the breast (2007) (99)
- Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. (2014) (98)
- Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. (2008) (98)
- Hodgkin's disease in homosexual men with generalized lymphadenopathy. (1985) (98)
- Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial (1985) (97)
- High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. (1996) (97)
- Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI) (2010) (89)
- Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. (2013) (88)
- The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. (1984) (88)
- Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. (1991) (86)
- Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. (2010) (84)
- Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. (1988) (82)
- Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). (2004) (81)
- Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. (1991) (80)
- Follicular large-cell lymphoma: intermediate or low grade? (1994) (80)
- Cancer survivorship : today and tomorrow (2007) (79)
- Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. (2012) (77)
- Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. (1982) (76)
- Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine (2007) (75)
- Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. (1997) (75)
- Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. (2000) (72)
- DETECTION OF B-CELL LYMPHOMA IN PERIPHERAL BLOOD BY DNA HYBRIDISATION (1985) (67)
- Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. (2007) (66)
- Phase I evaluation of a synthetic mutant of β-interferon (1985) (63)
- Something old, something few, something subjective, something déjà vu. (2003) (63)
- Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. (1996) (63)
- Expression of LFA‐1 in non‐hodgkin's lymphoma (1989) (62)
- Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma (2011) (61)
- Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). (2014) (61)
- Small lymphocytic lymphoma. (1989) (59)
- Burkitt's lymphoma--the message from microarrays. (2006) (58)
- Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update. (2004) (57)
- Hodgkin lymphoma in older patients: an uncommon disease in need of study. (2008) (56)
- Numbers of host "helper" T cells and proliferating cells predict survival in diffuse small-cell lymphomas. (1989) (50)
- Clinical significance of morphologic subdivision in diffuse large cell lymphoma (1991) (50)
- Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. (2007) (49)
- Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. (2007) (49)
- Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era (2015) (49)
- An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. (2013) (47)
- Follicular lymphoma: clinical features and treatment. (2008) (46)
- Diagnosis of B cell lymphoma by analysis of immunoglobulin gene rearrangements in biopsy specimens obtained by fine needle aspiration. (1986) (46)
- Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404) (2015) (45)
- Gynecomastia in testicular cancer patients prognostic and therapeutic implications (1985) (45)
- Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R‐CHOP) (2010) (44)
- CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma (1990) (43)
- Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis (2018) (42)
- Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease (2012) (42)
- Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate. (1987) (41)
- Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy. (1993) (41)
- Follow-up of adult cancer survivors: new paradigms for survivorship care planning. (2008) (41)
- Comparison of "host cell infiltrates" in patients with follicular lymphoma with and without spontaneous regression. (1988) (41)
- Hodgkin's disease: management of first relapse. (1996) (40)
- Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404) (2014) (40)
- Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. (1997) (38)
- Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin’s Disease (NLPHD). (2007) (37)
- Hodgkin's lymphoma: basing the treatment on the evidence. (2001) (37)
- The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. (2013) (36)
- Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin (2009) (36)
- Combined modality therapy for stage I-II large cell lymphoma. (1987) (36)
- Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). (2009) (35)
- Transferrin receptor expression by non‐hodgkin's lymphomas. Correlation with morphologic grade and survival (1988) (34)
- Non-Hodgkin lymphoma: influence of lymphography, CT, and bone marrow biopsy on staging and management. (1989) (34)
- Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402 (2016) (32)
- The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study. (2009) (32)
- Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). (2015) (32)
- The treatment of malignant histiocytosis. (1984) (31)
- Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkin’s Disease: Mature Data in Early and Advanced Stage Patients. (2004) (31)
- Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. (2015) (31)
- A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) (2010) (31)
- Risk, cure and complications in advanced hodgkin disease. (2007) (31)
- Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494 (2010) (30)
- Detection of non-Hodgkin's lymphoma in the peripheral blood by analysis of antigen receptor gene rearrangements: results of a prospective study. (1990) (30)
- Developing Standards for Breakthrough Therapy Designation in Oncology (2013) (29)
- Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. (2013) (29)
- Randomized phase 3 study in low‐grade lymphoma comparing maintenance anti‐CD20 antibody with observation after induction therapy: A trial of the ECOG‐ACRIN Cancer Research Group (E1496) (2016) (28)
- Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma (2015) (28)
- FDG-PET lymphoma demonstration project invitational workshop. (2007) (27)
- Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). (2006) (27)
- Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. (1994) (27)
- High-dose therapy and transplantation for low-grade lymphoma. (1997) (26)
- Age-related loss of trabecular bone in premenopausal women: A biopsy study (1983) (26)
- Autologous hematopoietic cell transplantation in Hodgkin's disease. (2000) (26)
- Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma : an Eastern Cooperative Oncology Group study ( E 1405 ) (2014) (25)
- Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment. (1989) (25)
- Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial (2012) (24)
- Primary refractory Hodgkin's disease. (1998) (24)
- Hodgkin's disease. (2002) (24)
- Long‐term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma (2012) (23)
- Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. (2007) (23)
- Future directions in radioimmunotherapy for B-cell lymphoma. (2003) (22)
- Follicular lymphoma, survival, and rituximab: is it time to declare victory? (2008) (22)
- Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497 (2007) (22)
- A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B‐cell non‐Hodgkin lymphoma: ECOG3402 (2015) (21)
- Gemcitabine is active in relapsed Hodgkin's disease. (1999) (21)
- Clinical and pathologic features of follicular large cell (nodular histiocytic) lymphoma (1987) (20)
- Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial (2007) (20)
- Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update (2007) (20)
- Treatment of early-stage Hodgkin's disease. (1999) (20)
- Follicular and diffuse mixed small-cleaved and large-cell lymphoma--a clinicopathologic study. (1985) (19)
- Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT). (2007) (19)
- Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation. (1986) (17)
- Hypercalcemia and vitamin d metabolism in Hodgkin's disease. Is there an underlying immunoregulatory relationship? (1990) (17)
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. (2010) (17)
- Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin’s lymphoma (NHL) (2005) (17)
- Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. (2000) (16)
- Survival in Follicular Lymphoma: The Stanford Experience, 1960–2003. (2007) (16)
- Current Stanford clinical trials for Hodgkin's disease. (1989) (16)
- Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab (2019) (15)
- Major histocompatibility complex class I and class II antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome. (1993) (15)
- A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma (1995) (15)
- The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. (2009) (14)
- R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793 (2010) (14)
- Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496 (2010) (14)
- Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options. (2000) (14)
- Original article: The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease (1992) (14)
- Role of FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. (2009) (14)
- NCCN preliminary non-Hodgkin's lymphoma practice guidelines. (1997) (14)
- Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial. (2009) (14)
- High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. (2006) (13)
- NCCN task force report: molecular markers in leukemias and lymphomas. (2009) (13)
- The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. (2014) (13)
- Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma. (1999) (13)
- Introduction: ASCO-ESMO Consensus Statement on Quality Cancer Care (2006) (12)
- A new cancer ecosystem (2017) (12)
- A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404) (2013) (12)
- Lymphocyte predominant Hodgkin’s disease (2002) (12)
- Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone (2012) (11)
- Retroperitoneal fibrosis following treatment for Hodgkin's disease. (1987) (11)
- Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. (2009) (11)
- Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. (2011) (11)
- AIDS and Hodgkin's disease. (1985) (11)
- Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant (2012) (11)
- Advances in the treatment of Hodgkin’s lymphoma (2000) (11)
- Management of advanced stage Hodgkin lymphoma. (2006) (10)
- Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma (2012) (10)
- Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499 (2017) (10)
- Recommendations for revised response criteria for malignant lymphoma. (2006) (10)
- MACOP‐B ± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices (1993) (9)
- Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). (2004) (9)
- Advances in the management of Hodgkin's and non-Hodgkin's lymphoma (1998) (8)
- Rituximab in stem cell transplantation for aggressive lymphoma. (2004) (8)
- Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404 (2008) (8)
- Phase I study of human leukocyte interferon in patients with advanced cancer. (1983) (8)
- Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University. (2006) (8)
- The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease. (1985) (8)
- Autologous Hematopoietic Cell Transplantation for Non‐Hodgkin's Lymphoma (2007) (7)
- Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496. (2011) (7)
- Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909 (2008) (7)
- Durable remissions in stage III follicular lymphoma: interpret with caution. (1987) (7)
- Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 (2011) (7)
- Treatment of refractory non-Hodgkin's lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin. (1987) (7)
- Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab (2005) (7)
- Comprar Hodgkin Lymphoma. A Comprehensive Update On Diagnostics And Clinics (Hematologic Malignancies) | Andreas Engert | 9783642127793 | Springer (2010) (6)
- Tumor-Infiltrating T Cells Are Not Predictive of Clinical Outcome in Follicular Lymphoma. (2006) (6)
- A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. (2012) (6)
- Early stage Hodgkin's disease: can we have our cake and eat it, too? (1996) (6)
- Long Term Results of Autologous Hematopoietic Cell Transplantation (AHCT) for Peripheral T Cell Lymphoma: The Stanford Experience. (2007) (6)
- Lymphocyte predominant Hodgkin's disease: more patience than patients. (2002) (6)
- Optimizing rituximab in B-cell lymphoma. (2005) (6)
- Phase I evaluation of a synthetic mutant of beta-interferon. (1985) (5)
- Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab. (2001) (5)
- Measuring granulocyte and monocyte accumulation at malignant lymphoma sites. (2009) (5)
- The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL). (2004) (5)
- Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas. (2006) (5)
- Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkin’s Disease (HD); the Stanford V + Radiotherapy (RT) Experience. (2005) (5)
- Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial (2016) (5)
- Phase I study of recombinant human interferon beta in patients with advanced cancer. (1987) (5)
- Abbreviated 8-week chemotherapy (CT) plus involved node radiotherapy (INRT) for nonbulky stage I-II Hodgkin lymphoma: Preliminary results of the Stanford G5 Study. (2011) (5)
- Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496 (2013) (5)
- Rituximab, Bevacizumab (Avastin) and CHOP (RA-CHOP) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL). (2004) (5)
- A prospective trial of involved field radiation (IFRT) + chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: Survival differences and implications of mature follow-up for current combined modality therapy (2007) (5)
- Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404) (2012) (4)
- Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience (2011) (4)
- Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493) (2012) (4)
- Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6 (2011) (4)
- Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL). (2005) (4)
- Understanding the validity of self-reported positive family history of lymphoma in extended families to facilitate genetic epidemiology and clinical practice (2007) (4)
- Hodgkin's Lymphoma (2008) (4)
- Immunoglobulin G Fc Polymorphism Is Correlated with Rituximab-Induced Neutropenia Following Autologous Hematopoietic Cell Transplantation. (2004) (4)
- Alternating chemotherapy and irradiation in advanced Hodgkin's disease (1984) (4)
- Recent advances in the treatment of Hodgkin's disease (1997) (3)
- Autologous Cytokine-Induced Killer Cells as Post-Transplant Cellular Immunotherapy. (2007) (3)
- Follicular Non-Hodgkin’s Lymphomas (1989) (3)
- Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab (2012) (3)
- The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease. (1992) (3)
- Toward defining an optimal therapy for hairy cell leukemia. (1989) (3)
- How much MOPP? (1989) (3)
- A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma (2005) (3)
- Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma (2013) (3)
- Cancer research and privacy: the problem with being joined at the hip. (2009) (3)
- Prognostic Indices in Older DLBCL Patients Receiving R-CHOP: An Analysis of the U.S. Intergroup Study (E4494, CALGB 9793). (2006) (3)
- Molecular biologic studies in the clinical evaluation of non-Hodgkin's lymphoma. (1991) (3)
- Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. (2009) (2)
- Recent advances in Hodgkin's disease. (1995) (2)
- Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma (2012) (2)
- A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial (2011) (2)
- Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin’s lymphoma: E1497 final report (2005) (2)
- Vincristine without a cap? So … (1994) (2)
- Management of Hematologic Malignancies: Hodgkin lymphoma: epidemiology, diagnosis, and treatment (2010) (2)
- Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003 (2008) (2)
- Mature Results of a Prospective Trial of Rituximab in Patients (Pt) with Post Transplant Lymphoproliferative Disorder (PTLD) Unresponsive or Ineligible for Reduced Immunosuppression (RIS). (2006) (2)
- Prognostic significance of p53/p21 expression in DLBCL treated with CHOP or R-CHOP: A correlative study of E4494 (2007) (2)
- Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years (2012) (1)
- Cardiovascular mortality following treatment of Hodgkin's disease (1989) (1)
- Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis (2015) (1)
- Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience. (2010) (1)
- Stage I/II Hodgkin’s Disease: Comparison of Outcomes of Patients with Bulky Mediastinal Disease Versus Other Risk Factors; the Stanford V Experience. (2007) (1)
- Tositumomab and Iodine I-131 Tositumomab (Bexxar® therapeutic regimen) for Non-Hodgkin's Lymphoma Patients Who Progressed After Treatment with Rituximab: Long Term Follow-up of a Multi-Center Phase II Study. (2009) (1)
- Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study (2011) (1)
- Patient priority in the era of patent expiries. (2014) (1)
- Phase I Trial ofToll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non^Hodgkin’s Lymphoma (2007) (1)
- Perspective of clinical research in follicular NHL: interaction between science and industry. (2011) (1)
- Expression of p 21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP : A Prospective ECOG and Southwest Oncology Group Correlative Study on E 4494 (2010) (1)
- A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402). (2012) (1)
- Serving interests in hematologic malignancies in the journal of clinical oncology. (2005) (1)
- lymphoma using pulsed-field gel electrophoresis Enhanced detection of the t(14;18) translocation in malignant (2011) (1)
- Recent advances in Hodgkin's disease (1995) (1)
- The health insurance portability and accountability act privacy rule and its impact on cancer research. (2009) (1)
- Maintaining life in indolent lymphoma from evidence-based medicine to clinical practicel (2009) (1)
- Plasma viral DNA as a marker of tumor response in EBV(+) Hodgkin lymphoma in a phase III study (E2496). (2012) (1)
- Halocercus in the lung of Delphinus delphis L. of the Adriatic. (1971) (0)
- the Stanford University Results and Prognostic Indices of Transplantation for Recurrent or Refractory Hodgkin's Disease: Analysis High-Dose Therapy and Autologous Hematopoietic Progenitor Cell (2013) (0)
- ‘ ‘ focus on . . . ’ ’ session : transformation 086 SNP ARRAY GENOTYPING IN 182 DIAGNOSTIC FOLLICULAR LYMPHOMA CASES IDENTIFIES SITES OF AUPD ASSOCIATED WITH OVERALL SURVIVAL AND RISK OF TRANSFORMATION (2008) (0)
- Craniosphud Irradiation for Acute Lymphoblastic Leukemia with Central Nervous System Disease at Diignosisz A Report from the Children's Cancer Group (1996) (0)
- Chapter 13 – THE NON-HODGKIN'S LYMPHOMAS: AN OVERVIEW (1985) (0)
- cell transplantation for aggressive non-Hodgkin's lymphoma Rituximab as adjuvant to high-dose therapy and autologous hematopoietic (2013) (0)
- Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement (2007) (0)
- Analysis of Breast Cancer Subtypes in Women who Develop Breast Cancer following Mantle Irradiation for Hodgkin's Disease (2010) (0)
- [Not Available]. (2006) (0)
- Left running head: HORWITZ et al. Right running head: RITUXIMAB AND AUTOTRANSPLANTATION FOR NHL Journal section: CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Rituximab as adjuvant to high dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin’s lymp (2003) (0)
- Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease (2010) (0)
- Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma (2013) (0)
- 60歳以上のDLBCL症例に対するR-CHOPとCHOPの第3相試験--導入療法後の奏功例に対してrituximab維持療法群と経過観察群に無作為化 (Hematology Symposium on Aggressive Lymphoma--Current Therapies for Aggressive Lymphoma in Japan,USA and Europe) -- (Session1 CHOP with or without Rituxan in previously untreated aggressive non-Hodgkin's lymphoma) (2004) (0)
- The Percentage of Tumor-Infiltrating T Cells Is Not Correlated with Overall Survival in Follicular B-Cell Lymphomas. (2004) (0)
- Allied in achieving the best-quality cancer care. (2006) (0)
- A prospective correlative study of Bcl-6 expression in diffuse, large B-cell lymphoma treated with CHOP or R-CHOP (2006) (0)
- LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study (2008) (0)
- Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease. (2009) (0)
- Intercurrent death following Hodgkin's disease therapy: radiotherapy, adjuvant mopp trials (1987) (0)
- Ef fi cacy of abbreviated Stanford V chemotherapy and involved-fi eld radiotherapy in early-stage Hodgkin lymphoma : mature results of the G 4 trial † (2013) (0)
- Transformed follicular lymphoma (1999) (0)
- Short Title: Survival in Follicular Lymphoma (2017) (0)
- Prognostic factors Identification of prognostic factors allows the design of risk-adapted therapy for early-stage Hodgkin’s lymphoma. Adverse prognostic factors described by the German Hodgkin Lymphoma Study Group (GHSG) and the European Organization for the Research and Treatment of Cancer (EORTC) (0)
- Hodgkin Lymphoma-ReadingSample (2014) (0)
- Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499 (2015) (0)
- From the editors (2006) (0)
- 126 Risk factors for febrile neutropemia among older patients with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) treated with anthracycline-based chemotherapy (2006) (0)
- 769 High dose therapy and autologous bone marrow transplantation for relapsed or refractory hodgkin's disease: The impact of total body irradiation and involved field radiation therapy (1995) (0)
- Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with low-grade non-Hodgkins lymphoma treated with tositumomab and iodine-131 tositumomab therapeutic regimen (2003) (0)
- 2523 : Long-term Outcomes of Survivors of Autologous Hematopoietic Cell Transplantation for Refractory/Relapsed Hodgkin’s Lymphoma (2006) (0)
- Non‐Hodgkin's Lymphoma (2009) (0)
- Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma. (2008) (0)
- Biomarkers in diffuse large B-cell lymphoma (2009) (0)
- Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). (2016) (0)
- Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. (2020) (0)
- Report o f a n I nternational W orkshop t o S tandardize Response C riteria f or N on-Hodgkin's L ymphomas (1999) (0)
- The Impact of Race and Socioeconomic Status (SES) on Survival in Non-Hodgkin’s Lymphoma (NHL): A Population-Based Study from the California Cancer Registry (CCR). (2007) (0)
- Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen (2010) (0)
- Positive phase III results for Roche ’ s emicizumab in haemophilia (2017) (0)
- Managing Indolent Lymphomas in Relapse (2000) (0)
- Combined modality therapy in the management of bulky mediastinal Hodgkin's disease (1990) (0)
- Roche ’ s Kadcyla reduced the risk of disease recurring in people with HER 2-positive early breast cancer with residual disease after neoadjuvant treatment (2018) (0)
- CVP alternating with fludarabine (CVP/F) chemotherapy prior to idiotype vaccination for follicular lymphoma (FL) (2007) (0)
- Outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the pre- and post-rituximab era: The Stanford University experience. (2011) (0)
- Should lymphocyte predominance Hodgkin’s disease be treated as a low grade lymphoma? (1999) (0)
- ASCO core values: essential to progress in innovative, quality cancer care. (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sandra J. Horning?
Sandra J. Horning is affiliated with the following schools:
